Progestogen-antiprogestogen regimens
AssigneeAkzo Nobel N.V.
InventorHerman Jan Tijmen Coelingh Bennink
Life of this patent
Estimating the term…
Abstract
An estrogen-free contraceptive is provided which does not have the bleeding-related drawbacks of conventional progestogen-only pills. Thus the invention is a contraceptive kit comprising a combined means for the simultaneous daily administration of a progestogen as the sole contraceptively effective ingredient and an anti-progestogen. Said combined means preferably is in the form of tablets having a normal contraceptive dose of the progestogen and low dose of the anti-progestogen.
Claims5
A method of treating intermenstrual bleeding in a female, the bleeding induced by administration to the female of a progestogen-only contraceptive regimen on a continuous daily basis, wherein the improvement comprises:
- co-administering, on the continuous daily basis for at least 28 consecutive days with the progestogen, an anti-progestogen at a daily dose equivalent, in anti-progestational activity, to a dose of (11β,17β)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl) estra-4,9-diene-3-one of from 0.05 mg to 5 mg to reduce bleeding in the female.
The method according to clam 1, wherein the daily dose of anti-progestogen is equivalent, in anti-progestational activity, to a dose of (11β,17β)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-diene-3-one of from 0.1 to 2 mg.
A method of contraception that inhibits ovulation in a female without increasing the frequency of intermenstrual bleeding, said method comprising:
- simultaneously administering to a female, every day for a period of at least 28 days, without a progestogen and anti-progestogen free day:
- progestogen in a daily dosage amount sufficient to inhibit ovulation in the female, and
- anti-progestogen in a daily dosage amount corresponding in anti-progestational activity to from 0.05 mg to 5 mg of (11β,17β)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-diene-3-one thus inhibiting ovulation in the female without increasing the frequency of intermenstrual bleeding.
Dependencies are inferred from the claim text.